Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Ethnopharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1452921
This article is part of the Research Topic Preventive Potential of Antioxidants in Age-Related Diseases View all 4 articles

Dihydromyricetin ameliorate postmenopausal osteoporosis in ovariectomized mice: Integrative microbiomic and metabolomic analysis Author names

Provisionally accepted
Lei Xu Lei Xu 1Xianze Sun Xianze Sun 2*Hui Li Hui Li 1*Xiaoqiang Han Xiaoqiang Han 1*Xiaoqiong Li Xiaoqiong Li 3*Liying Zhu Liying Zhu 3*Xin Wang Xin Wang 3*Jinjun Li Jinjun Li 3*Haibiao Sun Haibiao Sun 1*
  • 1 Shanxi Medical University, Taiyuan, China
  • 2 University of Technology Sydney, Sydney, New South Wales, Australia
  • 3 Zhejiang Academy of Agricultural Sciences, Hangzhou, Zhejiang, China

The final, formatted version of the article will be published soon.

    The gut microbiota may help mitigate bone loss linked to postmenopausal osteoporosis by affecting the immune and inflammatory responses and the gut-bone axis. Dihydromyricetin (DMY), a natural flavonoid, has some anti-inflammatory and antioxidant properties. This study aimed to investigate the mechanisms underlying the amelioration of bone loss in ovariectomized (OVX) mice treated with various doses of DMY. Eight-week-old C57/BL6 mice underwent ovariectomy and received varying DMY doses over 8 weeks. Thereafter, femoral bone microarchitecture, serum biomarker levels, and colon samples were analyzed to assess bone metabolism and inflammatory and hormonal responses. Fecal samples were subjected to 16S rDNA sequencing, and short-chain fatty acids were quantified. An untargeted metabolomics approach was applied to both serum and fecal samples to investigate alterations in the intestinal microbiota and metabolic profiles following DMY treatment in the OVX mice.The results show high-dose DMY has anti-osteoporotic effects. Compared to the OVX group, the DMY-treated group showed enhanced bone mineral density and 2 reduced inflammation and colonic damage levels. The DMY treatment altered the gut microbiota composition, including the relative abundances at both the phylum and genus levels. In addition, DMY treatment increased the production of acetate and propionate. Metabolomic analysis revealed differential regulation of 37 and 70 metabolites in the serum and feces samples, respectively, in the DMY-treated group compared to those in the OVX group, affecting the serotonergic signaling, arachidonic acid metabolism, and unsaturated fatty acid biosynthesis pathways. In conclusion, these findings indicate that DMY can ameliorate bone loss in OVX mice via the gutbone axis.

    Keywords: bone loss, dihydromyricetin, gut microbiota, ovariectomized mice, CT, computed tomography, CTX-1, C-terminal telopeptide of type I collagen, DMY, dihydromyricetin, DMY_L, low-dose DMY group, DMY_H, highdose DMY group, E2, estradiol, IL-6, interleukin-6, OPG, Osteoprotegerin

    Received: 21 Jun 2024; Accepted: 12 Sep 2024.

    Copyright: © 2024 Xu, Sun, Li, Han, Li, Zhu, Wang, Li and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xianze Sun, University of Technology Sydney, Sydney, 2007, New South Wales, Australia
    Hui Li, Shanxi Medical University, Taiyuan, China
    Xiaoqiang Han, Shanxi Medical University, Taiyuan, China
    Xiaoqiong Li, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310000, Zhejiang, China
    Liying Zhu, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310000, Zhejiang, China
    Xin Wang, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310000, Zhejiang, China
    Jinjun Li, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310000, Zhejiang, China
    Haibiao Sun, Shanxi Medical University, Taiyuan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.